# Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

> **NCT04585737** · PHASE4 · COMPLETED · sponsor: **Charlotte-Paige Rolle, MD** · enrollment: 222 (actual)

## Conditions studied

- HIV I Infection

## Interventions

- **DRUG:** Dolutegravir / Lamivudine Pill
- **DRUG:** Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill

## Key facts

- **NCT ID:** NCT04585737
- **Lead sponsor:** Charlotte-Paige Rolle, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-05
- **Primary completion:** 2023-08-03
- **Final completion:** 2023-08-10
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2024-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04585737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04585737, "Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04585737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*